Body Composition

Retatrutide

Retatrutide (Triple GIP/GLP-1/Glucagon Agonist)

Triple-hormone agonist drawing intense metabolic-research interest

Research Status: Investigational; Phase II data published LY3437943 Triple-G
Mechanism of Action

How it works

Retatrutide simultaneously activates the GIP, GLP-1, and glucagon receptors. Adding glucagon-receptor activity is thought to increase energy expenditure alongside the appetite and insulin effects of the incretin receptors.

Areas of Research

What the research explores

In published research, Retatrutide has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.

  • Among the highest weight reductions reported for an incretin agent in trials
  • Triple-receptor mechanism studied for energy expenditure
  • Investigated for glycemic and hepatic-fat markers
  • Researched in obesity and metabolic dysfunction
  • Active area of clinical investigation
Research Highlight

A 2023 Phase II trial reported mean body-weight reductions around 24% at the highest dose over 48 weeks, drawing wide attention.

Safety Profile

Adverse events & gaps

Investigational - safety still being characterized. Gastrointestinal effects most commonly reported in trials.



Stay Informed on
Peptide Research

Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.

No spam. Unsubscribe at any time.